Eli Lilly, Juvena Therapeutics Partner to Develop Muscle-Boosting Drugs Using AI Platform

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a partnership with Juvena Therapeutics to develop new muscle-boosting drugs. The collaboration is valued at over $650 million, with the majority of this sum tied to the achievement of specific development and commercialization milestones.

The core of the partnership involves Eli Lilly using Juvena’s AI-enabled screening platform, which is known as JuvNET. This platform specializes in mapping the therapeutic potential of proteins secreted by stem cells. By combining a vast database of secreted proteins with disease phenotypes, in silico and in vitro human cell screening, and other advanced capabilities, JuvNET is designed to identify promising drug candidates that can improve muscle health and body composition.

Eli Lilly’s interest in muscle-boosting drugs has surged in parallel with the popularity of GLP-1 weight-loss medication. These medications are effective for weight loss but can also lead to a reduction in lean muscle mass, which can impair physical function and increase the risk of falls and fractures, especially in older individuals and senior citizens. Eli Lilly aims to address this concern.

Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals internationally. Juvena Therapeutics is a clinical-stage biotechnology company on a mission to research, develop, and commercialize tissue restorative biologics.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.